The binding of cytokines to their receptors occurs over large surfaces on both the ligand and receptor, as exemplified by the crystal structure of growth hormone (GH) bound to its receptor. The structure of the GH complex shows that more than 30 side chains on the hormone surface and on each of the two receptor subunits are buried on binding (1) . Of these many residues, however, only three, clustered in a very small area on each receptor, contribute 75 percent of the binding energy (2) . If proteins generally bind one another through small epitopes, the potential for finding small molecule ligands is good.
New methods for ligand discovery are based on combinatorial procedures for assembling large numbers of compounds to produce diverse molecular shapes testable for binding molecular targets (3, 4) . Because of the numbers of compounds produced, it is necessary to employ methods for testing the compounds in pools, rather than individually. Vast libraries of peptides can be created through cloning complex mixtures of combinatorially synthesized oligonucleotides into specialized expression "display" vectors. The filamentous phage display system, whereby the expressed peptides are displayed as fusions to phage coat pro- teins, has been effective in the discovery of ligands (5) (6) (7) (8) . Affinity purification of the population of phage particles on the target protein is used to recover peptides with binding activity. Sequencing the appropriate segment of the DNA of each captured phage provides the primary sequence of peptides that bind the target.
We used the filamentous phage method to search for peptides that would bind to the extracellular domain of the human EPO receptor (EPOR), and to derive from such ligands compounds capable of stimulating erythropoiesis. The primary regulator of erythropoiesis, which is a complex process of cellular differentiation and proliferation resulting in the production of red blood cells, is the glycoprotein hormone EPO (9, 10) . Human EPO is a 34-kD monomeric molecule composed of 165 amino acid residues (18.5 kD) and an almost equivalent mass of carbohydrate. The structure of EPO is predicted to be a bundle of four ao helices, sharing common secondary structure motifs and tertiary fold with other members of the family of hematopoietic growth factors of known three-dimensional structure (1 1, 12) .
The biological effects of EPO are exerted through binding to the EPOR, which is expressed on the surface of target cells ( 13, 14) . The EPOR belongs to the hematopoietic cytokine receptor family, which includes receptors for most of the interleukins and various other hematopoietic and nonhematopoietic growth factors (12, 15, 16) . These receptors are type I cell surface proteins composed of an NH2-terminal ligand binding domain, a COOH-terminal cyto|Emnu plasmic region, and a single membranespanning domain. Conserved features of the extracellular domain include two pairs of cysteine residues and a "WSXWS" motif (17) with characteristic spacing. The receptor is believed to become activated after homodimerization (18) (19) (20) , possibly by the mechanism established for GH receptor (1, 21) , where the monomeric hormone molecule binds to and causes the dimerization of two identical receptor chains. This proposed mechanism is supported, in part, by the finding that a constitutively active EPOR containing a single point mutation (R129C) in the extracellular domain exists as a homodimer (22) . Although the receptor shows no intrinsic kinase activity, protein tyrosine phosphorylation plays a pivotal role in EPOR signal transduction (23, 24) , through the activation of receptorassociated tyrosine kinases (25, 26) .
Recombinant human EPO has a role in the treatment of anemia associated with certain pathological conditions (27, 28) . As a glycoprotein, EPO must be administered either by intravenous or subcutaneous injection. In seeking smaller molecules to serve as lead compounds in the development of a more conveniently delivered agent, and to acquire structural probes of the receptor, we characterized the recovered peptide ligands for EPOR binding and specificity, and for EPO-mimetic properties in receptor activation assays. We showed that these peptides have the ability to specifically activate an erythropoietic response in cell-based assays and in animals. The structure of a complex of one of these peptides with the EPOR has been described by Livnah et al. (29) and elucidates the mechanism by which receptor activation is achieved.
Identification and optimization of ligands to EPOR. The isolation of peptides that bind and activate the EPOR was facilitated by the availability of a soluble form of the EPOR extracellular domain (ECD) that binds EPO with an affinity similar to that reported for the full-length receptor (13, 14) . We expressed the EPOR ECD in Chinese hamster ovary cells as a fusion protein to aid in purification and immobilization by a method that has been used for other type I receptors (30) (31) (32) . The COOH-terminal signal sequence of the human placental alkaline phosphatase (HPAP) was fused to the carboxyl terminus of the EPOR ECD. This signal sequence directed the expression of the truncated receptor to the cell surface where it is anchored by a phosphatidylinositide glycan linkage. Soluble EPOR (sEPOR) was obtained by treating the cells with phospholipase C and was immobilized in polystyrene wells by a monoclonal antibody (mAb) to the HPAP domain 458 SCIENCE * VOL. 273 * 26 JULY 1996 (mAbl79). The dissociation constant (Kd) of recombinant human EPO (rhEPO) for this immobilized sEPOR was about 200 pM, a value similar to that found for the native receptor expressed on cells of the erythroid lineage (13) (Fig. 1A) . Initial attempts to isolate EPOR-specific clones relied on acid elution to recover phage and were unsuccessful. We therefore modified the sEPOR by the insertion of a protease (thrombin) cleavage site between an the ECD and HPAP domains. This modification, which had minimal effect with respect to ligand binding, allowed us to use thrombin cleavage instead of acid elution to liberate only those phage particles bound to the sEPOR. Using the thrombin release procedure (33), we isolated a receptor-specific clone (designated C2/11) from a library of cyclic 8-residue peptides displayed on pVIII (34). An enzyme-linked immunosorbent assay (ELISA) was used to demonstrate EPOR-binding activity. This clone did not bind to mAbl79, bovine serum albumin (BSA) or to the extracellular domains of the receptors for tumor necrosis factor (TNFR-p55), nerve growth factor (NGFR), interleukin-2 (IL2Rcx, -,B, and -,y subunits) and E-selectin (35). Furthermore, EPO was found to compete with clone C2/11 for binding to the immobilized sEPOR (35).
The DNA insert encoding the peptide displayed by clone C2/11 was sequenced, and the peptide sequence was deduced to be CRIGPITWVC (17) . This peptide, designated AF11154, was synthesized to include two pairs of glycine residues flanking the library peptide sequence (as contained in all peptides in the library) and oxidized to the intramolecular disulfidebonded (cyclic) form. The structure of the purified synthetic peptide was confirmed by mass spectrometry. This peptide was capable of competing with 1251I-labeled EPO binding to immobilized sEPOR with an apparent affinity of approximately 10 pM (Table 1 and Fig. 1B ). This confirmed the ability of the peptide to bind the receptor when removed from the context of fusion with pVIII. Furthermore, the peptide did not compete for binding of either human IL-13 to the human IL-1 type II receptor, or human IL-2 to the human IL-2 receptor a,3 hetero-dimer (35).
To obtain peptides with higher affinity, we performed phagemid display mutagenesis (30, 32) . We used the lower valency pIlI phagemid display system in which 0 to 5 copies of fusion protein are expressed per particle, in contrast to 100 to 200 copies of peptide displayed in the pVIII system. Mutagenesis libraries were screened with the use of an EPO elution step to enrich for higher affinity (NGFR),T 100) (Fig. 2) . BecaLlse of the quantity of EPOR-binding clones isolated from this library, we devised a strategy to identify those of higher affinity. We developed an elution ELISA format in which EPORbound phagemids were allowed to dissociate in the presence of EPO (38). The reduction in signal when compared to a noneluted sample was used as a possible indication of ligand affinity. Five peptides chosen on the basis of their signals in this assay were synthesized in the cyclic (disulfide-bonded monomer) form (Table 1) . The affinities of these peptides in the immobilized EPOR binding assay were established (Table 1) , and the peptides showed a 10 to 50 times higher affinity than that shown by the parental peptide ligand AF11154 (Fig. 1B) . The importance of the disulfide bond was demon- OmminiNIuium strated by testing linear analogues of the peptides in which either or both of the cysteine residues were mutated to serine. These were at least 1000 times lower in binding affinity (35). The five peptides chosen for synthesis are representative of two highly conserved features within the family of sequences. The first, arising within the mutated core sequence between the fixed cysteines, is the absolute conservation of GPXTW motif, suggestive of a 1-turn motif. The almost perfect conservation of a tyrosine outside the disulfide loop was also reflected in the peptides synthesized for testing. It is probable that the selection of this tyrosine residue accounted, in part, for the substantial increase in affinity for the sEPOR. Furthermore, the frequency of proline in the COOH-terminal flanking sequence indicates its possible importance as a binding determinant. These hypotheses are supported by the crystal structure of a co-complex of a representative EPOR agonist peptide with the extracellular domain of the human EPOR (29) . This structure confirms that the GPLT sequence resides in a 1 turn that also makes contacts with the receptor. The tryptophan residue of the GPXTW motif contributes to stabilization of the peptide structure, whereas the tyrosine constitutes an additional, important receptor contact point.
EPO-mimetic activity of peptides in biological assays in vitro and in vivo. To evaluate the biological potential of the peptides on EPO-responsive eukaryotic cell lines, we constructed an EPO-responsive line by transfecting FDCP-1 cells with the full-length human EPOR, as described for the murine EPOR (39). EPO stimulates this line to proliferate, with half maximal response (EC50) occurring at 10 to 20 pM (Fig.  3A) . The parental line did not respond to EPO, but retained the growth requirement of a supplement of WEHI-3 conditioned media (40, 41) . The low affinity peptide ligand, AF 1154, was inactive in this assay at concentrations up to 200 jiM (35). However, the higher affinity peptides were found to be full EPOR agonists, supporting cell proliferation and producing the same maximal proliferative response as EPO (Fig. 3B) . For this reason the nomenclature "EPO mimetic peptide" (EMP) was adopted. The peptides did not activate the FDCP-1 parental cell line, thereby demonstrating that the proliferative effect was dependent on the presence of the EPOR (35)
To confirm that the activity was due to the peptide and not the result of any contamination by EPO, we performed a proliferation assay with EMP4 and FDCP-1/hEPOR cells in which a rabbit polyclonal EPO neutralizing serum was superimposed at a 1 percent concentration on top of both standard EPO and peptide curves. The activity of EPO was almost totally inhibited by the antiserum. The proliferative response to EMP4, however, was not diminished, by the antiserum (35). The EPO-mimetic bioactivity of EMP4 and EMP5 on the murine EPOR (mEPOR) was also assayed with FDCP-1 cells transfected with the fulllength mEPOR (FDCP-1/mEPOR). Both were active on these cells (35).
One of the more active peptides, EMPI, (47) , which are stimulated by progestin and serum, respectively (41) . A further indication of the peptide specificity for erythropoietin receptor-bearing cell lines was its lack of activity on a human T cell clone (41) that is responsive to interleukin-2 (48).
To assess the activity of EMP1 in supporting the expansion and differentiation of cells of the erythroid lineage, we performed colony assays with human bone marrow. Cells were plated in methylcellulose medium containing either peptide (1 puM and 10 ,uM), rhEPO (0.24 nM), or a combination of the recombinant human growth factors interleukin-3 (IL-3, 0.7 nM), granulocytemacrophage colony-stimulating factor (GM-CSF, 0.7 nM), and stem cell factor (SCF, 2.7 nM). A control culture received no additional factors or peptide. Plates were incubated for 12 days, after which erythroid colonies (CFU-E) and granulocyte-macrophage colonies (CFU-GM) were counted ( Table 2) . No colonies grew in the absence of additional factors or peptide. In cultures receiving peptide alone, the production of erythroid colonies was supported in a dosedependent manner. The effect of the peptide was shown to be erythroid-specific by the effective absence of CFU-GM in these cultures compared to the control containing factors known to support their growth (IL-3, GM-CSF, and SCF). This is in agreement with the cell culture results in which EMP1 did not stimulate M07e (44) or AML193 (45), two cell lines that respond to GM-CSF, but not to EPO. EMP1 was also active in promoting erythroid colony formation from human peripheral blood and murine bone marrow (41) . An examination of the specific and temporal intracellular events induced on stimulation with either EPO or EMP1 was undertaken to determine if similar signaling pathways were utilized by both the natural and mimetic EPOR ligands. The binding of EPO to its receptor causes rapid phosphorylation of cellular substrates on tyrosine residues, most likely due to the activation of JAK2 (25, 26) . A number of proteins phosphorylated on tyrosine residues after EPO stimulation have been identified (25, (49) (50) (51) . The pattem of protein tyrosine phosphorylation following a 10-minute stimulation of FDCP-1/mEPOR cells by EPO or EMPl was examined by Westem blot analysis utilizing an anti-phosphotyrosine monoclonal antibody. EPO induced the phosphorylation of proteins with apparent molecular weights of 140, 95, 70, and 55 kD (Fig. 4) . These proteins most likely correspond to JAK2 (25) , vav (49) , EPOR (51), and shc (50), respectively. When compared to EPO, EMP1 produced an identical phosphorylation pattern.
Another indication that EMPI and EPO use same signaling pathway was the findingthat similar cell-cycle kinetics were induced by both ligands. Factor-starved FDCP-1/ mEPOR cells were stimulated with either EPO or EMP1 and analyzed by propidium iodide staining and flow cytometry at the indicated time intervals (Fig. 5) . After 18 hours in the absence of either factor, the majority of the cells were in Go/Gl. Eight hours after the cells were stimulated, approximately 35 percent were in S phase in both EPO and peptide-treated cultures. Continued incubation (10 and 12 hours) and analysis of cells treated with either agent resulted in comparably increased progression into S phase. EMPI was tested in vivo for EPO mimetic activity in two mLrine models of erythropoiesis. The first was an assay in which normal, untreated mice containing endogenous basal levels of EPO were used (52) . Reticulocyte counts (erythrocyte precursors) in peripheral blood were determined by flow cytometry after mice were treated with various amounts of either EPO or peptide (Fig. 6A) . At the highest doses of EPO tested (40 units), the increase in reticLlocytes was approximately 15 percent. A smaller, but significant increase of approximately 6 percent resulted from the administration of peptide (2 mng), demonstrating that EMPI can induLce the produLction of reticulocytes over tlhe background of endogenous-EPO in this animal model. A second, more sensitive assay, the exhypoxic-polycythemic mouse bioassay, was used to assess further the in vivo activity of the peptide (53) . This assay relies on the induction of polycythemia by conditioning mice in a hypobaric chamber to suppress endogenous EPO production. Increases in 59Fe incorporation into blood can be attributed to exogenously administered erythropoietic agents. A dose response was produced over the range of EPO administered (0.025 to 0.100 U) (Fig. 6B) . At the highest dose of EPO, approximately 16 percent of total counts were incorporated (vehicle and DMSO backgrounds 1 percent and 2 percent, respectively). EMPI also showed a dose-dependent response in this assay, with detectable activity over the entire range tested (1.0 to 54.0 wg per mouse). At a dose of 54 pLg of peptide per mouse, the amount of 59Fe incorporated was equivalent to that observed for 0.10 U of EPO per mouse. Implications of these findings. We have isolated and characterized a family of cyclic peptides with erythropoietic activity. We initially identified an eight-amino acid peptide sequence by screening libraries of random peptides displayed on filamentous phage. This sequence served as the starting point for the development of a family of larger, closely related peptides with enhanced binding affinity and EPOR agonist activity. None of the EPOR peptide ligands that we identified had homology with the primary sequence of EPO. The EPOR-dependent agonist activity was demonstrated in various cell lines containing either the recombinant or native EPO receptors of both human and murine origin. A representative peptide (EMPI) was found to induce a pattern of tyrosine phosphorylation indistinguishable from that produced by stimulation with human EPO. That these properties were mediated through the EPOR and were not a result of general mitogenic effects was shown by the inability of the peptide to promote growth of cells responsive to factors other than EPO. Remarkably, these agonist properties extend to in vivo models of erythropoiesis.
Phage display technology proved to be instrumental in both the initial discovery of the peptide ligand and the selection of higher affinity agonists. Essential to this process was a receptor engineered to permit the specific release of receptor-phage complexes by proteolytic release of immobilized receptor. Despite exhaustive screening of many libraries, we recovered receptor-specific ligands only from a library of disulfidecyclized peptides. Furthermore, linear analogues of the active cyclic peptides made by mutagenizing either or both of the flanking cysteine residues to serine had a binding affinity that was at least 1000 times lower and exhibited undetectable agonist activity (35).
A surprising property of these peptides was the ability to activate a growth factor receptor. A growing body of evidence implicates the role of cytokine-mediated receptor dimerization in the initiation of signal transduction, as initially shown for growth hormone receptor activation (1). Here we have shown that peptides of approximately 2 kD can bind in the EPO binding site of the EPOR and mimic the action of the 34-kD growth factor. Furthermore, non-disulfide-mediated, covalently linked dimeric forms of EMPI (made by means of two different strategies) have significantly increased potency in the EPOdependent proliferation assay (35, 54, 55) . Selection from the initial library and subsequent analog libraries was based solely on receptor binding and not receptor activation; however the process recovered peptides that not only bound but also triggered a receptor response indistinguishable from that produced by EPO. A possible explanation of this result is that immobilization of the receptors at high density on an array of immunoglobulin G molecules presents the ligand binding sites in close proximity, allowing the capture of ligands contacting both receptor molecules simultaneously.
When bound to a bacterially expressed form of the EPOR ECD (56), the peptides promote the formation of diffractable crystals of the complex. Livnah et al. (29) describe the structure of this complex at a resolution of 2.8 A; and the structure reveals the mechanism by which the peptides can induce the erythropoietic response. Two peptide molecules, each contacting both receptor subunits, interact with one another in a nearly symmetric array to dimerize the receptors.
The EPO-mimetic peptide has yet another property; the ability to elicit an erythropoietic response in vivo. This activity did not depend on either a special formulation or chemical modification of the peptide. In addition, the dosing regimens for the in vivo bioassays were based on protocols previously established for EPO, and may not be optimal for administration of the peptide. Because of the commonly accepted generalization that L-peptides are rapidly degraded in serum, our finding of activity in the animals was unexpected. We have determined that in this case the generalization does not apply; the half-life of isolated EMPI in 50 percent fresh mouse serum is approximately 8 hours (54) . This stability may account, in part, for the ability of the peptide to exert its effect in vivo. Nevertheless, the peptide is less potent, compared with EPO, in the mouse than would be expected on the basis of its activity in vitro. This is likely due to the rapid clearance of the peptide from the circulation by well-462 SCIENCE * VOL. 273 * 26 JULY 1996 known mechanisms of uptake into kidney, liver, and other tissues. The bound structure of the peptides may serve as a guide in designing individual small molecule mimetics, or small molecule libraries to reselect against the EPOR. Small molecule EPO mimetics may have desirable pharmacological properties such as oral availability or the ability to be delivered trans-dermally, neither of which has been achieved for EPO. The general utility of this approach to the discovery of agonists of other cytokine receptors remains to be demonstrated.
